

THE COVID-19 CRIMINAL LIABILITY CASE

*A Citizen's Indictment Against the Government of Canada for Crimes of
Democide*

Prepared under Canadian Law, the Constitution Act, and International Legal Obligations

I. Criminal Allegations

- ****1. Criminal Negligence Causing Bodily Harm and Death (Criminal Code ss. 219–221)****
- ****2. Breach of Trust by Public Officer (Criminal Code s. 122)****
- ****3. Common Nuisance (Criminal Code s. 180)****
- ****4. Intimidation and Extortion (Criminal Code ss. 264.1 & 346)****
- ****5. Fraud Over \$5,000 (Criminal Code s. 380(1))****
- ****6. Criminal Conspiracy (Criminal Code s. 465)****

II. Supporting Exhibits and Evidence

- - Pfizer 5.3.6 Post-Authorization Safety Report (FOIA, 2021)
- - EbMC Yellow Card Summary (UK, 2021)
- - Health Canada FOIA (No SARS-CoV-2 isolation)
- - CDC VAERS (2021–2023)
- - Statistics Canada Excess Mortality (2021–2024)
- - FDA EUA Memorandum (Dec 2020)
- - ICCPR Articles 6, 7, 9
- - Nuremberg Code, Helsinki Declaration

III. Remedies and Demands

- 1. Independent criminal investigation
- 2. Criminal referrals of responsible officials
- 3. Moratorium on mRNA injections
- 4. Subpoena-backed public inquiry
- 5. Reparations for victims

IV. Declaration

"Crimes were committed in the name of public health. People died, were injured, silenced, and shamed. The law was broken. Trust was shattered. And justice now demands to be served."

Appendix A: Core Exhibits and Documents

- 1. Pfizer 5.3.6 Post-Authorization Safety Report
- 2. VAERS Summary Report (Sept 2021)
- 3. FOIA Response from NRC (No SARS-CoV-2 Isolation)
- 4. CDC Excess Mortality Data
- 5. Australian Public Health Act (ADF Injection Authorization)
- 6. FDA EUA Document for Pfizer-BioNTech
- 7. ICCPR, Articles 6–9
- 8. Nuremberg and Helsinki Declarations

Appendix B: Visual Exhibits

Figure B1. Pfizer Post-Marketing Data

BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021

090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)

Report Prepared by:

Worldwide Safety

Pfizer

The information contained in this document is proprietary and confidential. Any disclosure, reproduction, distribution, or other dissemination of this information outside of Pfizer, its Affiliates, its Licensees, or Regulatory Agencies is strictly prohibited. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes.

Figure B2. VAERS Myocarditis Spike

THE VACCINE DEATH REPORT

THE **VACCINE DEATH** REPORT

Is there evidence of millions of deaths and serious adverse events
resulting from the experimental COVID-19 injections?

BY DAVID JOHN SORENSEN & DR. VLADIMIR ZELENKO MD
VERSION **1.0** SEPTEMBER 2021

PURPOSE

The purpose of this report is to document how all over the world millions of people have died, and hundreds of millions of serious adverse events have occurred after injections with the experimental mRNA gene therapy. We also reveal the real risk of an unprecedented genocide.

FACTS

Our aim is to only present scientific facts, and stay away from unfounded claims. The data is clear and verifiable. References can be found with all presented information, which is provided as a starting point for further investigation.

COMPLICITY

The data suggests that we may currently be witnessing the greatest organized mass murder in the history of our world. The severity of this situation compels us to ask this critical: will we rise up to the defense of billions of innocent people? Or will we prefer personal profit over justice, and be complicit? Networks of lawyers all over the world are preparing class action lawsuits to prosecute all who are serving this criminal agenda. To all who have been complicit so far, we say: there is still time to turn and choose the side of truth. Please make the right choice.

WORLDWIDE

Although this report focuses on the situation in the United States, it also applies to the rest of the world, as the same type of experimental injections with similar death rates - and comparable systems of corruption to hide these numbers - are used worldwide. Therefore we encourage everyone around the world to share this report. May it be a wake up call for all of humanity.

STOPWORLDCONTROL.COM

Figure B3. Health Canada FOIA – Virus Not Isolated



National Research Council
Canada

Conseil national de recherches
Canada

ATIP Office
1200 Montreal Road
Building M-55
Ottawa, Canada
K1A 0R6

ATIP.AIPRP@nrc-cnrc.gc.ca

Bureau de l'AIPRP
1200 chemin Montréal
Édifice M-55
Ottawa, Canada
K1A 0R6

NRC · CNRC

July 14, 2020

Our file: A2020-0010
PROTECTED

Christine Massey, M.Sc.
#221 - 93 George St. S.
Brampton, ON
L6Y 1P4

Dear Christine Massey:

This letter is in response to the request you made to the National Research Council (NRC) under the *Access to Information Act* for records pertaining to:

“All records in the possession, custody or control of the National Research Council of Canada (NRC) describing the isolation of a SARS-COV-2 virus, directly from a sample taken from a diseased patient, where the patient sample was not first combined with any other source of genetic material (i.e. monkey kidney cells aka vero cells; liver cancer cells).”

Please note that I am using “isolation” in the every-day sense of the word: the act of separating a thing(s) from everything else. I am not requesting records where “isolation of SARS-COV-2” refers instead to:

- ***the culturing of something, or***
- ***the performance of an amplification test (i.e. a PCR test), or***
- ***the sequencing of something.***

Please also note that my request is not limited to records that were authored by the NRC or that pertain to work done by the NRC. My request includes any sort of record, for example (but not limited to) any published peer-reviewed study that the NRC has downloaded or printed.

If any records match the above description of requested records and are currently available to the public elsewhere, please provide enough information about each record so that I may identify and access each record with certainty (i.e. title, author(s), date, journal, where the public may access it).”

Your request was received by the NRC on June 13, 2020, and your application fee was received and processed on June 19, 2020.

A thorough search of NRC's records has now been completed, and we regret to inform you that no records responsive to your request were identified.

Figure B4. Australian ADF Injection Authorization

PUBLIC HEALTH ACT 2016 (WA)

**INSTRUMENT OF AUTHORISATION
AUTHORISATION TO SUPPLY OR ADMINISTER A POISON
[SARS-COV-2 (COVID-19) VACCINE - AUSTRALIAN DEFENCE FORCE]
(No. 2) 2021**

1. I, Dr Andrew Robertson, Chief Health Officer (WA), acting pursuant to sections 197 and 198 of the *Public Health Act 2016* (WA) [the Act] that gives power, for the purposes of emergency management during a public health state of emergency, to authorise a person to supply or administer a poison, hereby authorise the person(s) occupying the class of position in Column 1 of the attached Schedule to perform the statutory functions in Column 2 of the attached Schedule, subject to the conditions, limitations or restrictions (if any) set out in Column 3 of the attached Schedule.
2. The Schedule is attached as Annexure A.
3. This instrument of authorisation shall take effect from 8 March 2021 and shall remain in force until the public health state of emergency is no longer in force or until otherwise amended or revoked.
4. This instrument of authorisation is additional to the *Instrument of Authorisation - Authorisation To Supply Or Administer A Poison [SARS-COV-2 (COVID-19) VACCINE] (No. 1) 2021*.

DATED this 5th day of March, 2021


Dr Andrew Robertson
CHIEF HEALTH OFFICER

Appendix D: Scientific & Forensic Evidence

Figure D1. Pfizer LNP Biodistribution to Liver and Ovaries

Page 1

SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048)
2.6.4 Summary of pharmacokinetic study

Masking location: Adjusting

TABLE OF CONTENTS

LIST OF TABLES	1
LIST OF FIGURES	1
Terms and abbreviations used in this section	2
1. Summary	3
2. Analytical method	Four
3. Absorption	Four
4. Distribution	Five
5. Metabolism	7
6. Excretion	9
7. Pharmacokinetic drug interactions	9
8. Other pharmacokinetic studies	9
9. Discussions and conclusions	9
10. Chart	Ten
References	Ten

LIST OF TABLES

Table 1 Luciferase RNA-encapsulated LNP intravenously to Wistar Han rats at a dose of 1 mg RNA / kg Pharmacokinetics of ALC-0315 and ALC-0159 when administered orally	Four
---	------

LIST OF FIGURES

Figure 1 Luciferase RNA-encapsulated LNP venous in Wistar Han rats at a dose of 1 mg RNA / kg Plasma and liver concentrations of ALC-0315 and ALC-0159 when administered orally	5
Figure 2 In vivo in BALB / c mice intramuscularly administered with luciferase RNA-encapsulated LNP Luminous	6
Figure 3 Estimated in vivo metabolic pathway of ALC-0315 in various animal species	8
Figure 4 Estimated in vivo metabolic pathway of ALC-0159 in various animal species	9

PFIZER CONFIDENTIAL
Page 1

Page 2

Masking location: Adjusting

Figure D2. Metallic Contaminants in Vaccine Vials (SEM/EDX)

Investigation of metallic contaminations found
in vector- and mRNA-based
COVID-19-”vaccines”
- Preliminary results -

March 2022

Figure D3. NTI Monkeypox Pandemic Simulation Timeline



Jaime M. Yassif, Ph.D.
Kevin P. O'Prey, Ph.D.
Christopher R. Isaac, M.Sc.

NTI:bio

Appendix D Continued: Forensic Source Pages

Figure D1.1 – Pfizer LNP Distribution (Page 1)

Page 1

SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048)
2.6.4 Summary of pharmacokinetic study

Masking location: Adjusting

TABLE OF CONTENTS

LIST OF TABLES	1
LIST OF FIGURES	1
Terms and abbreviations used in this section	2
1. Summary	3
2. Analytical method	Four
3. Absorption	Four
4. Distribution	Five
5. Metabolism	7
6. Excretion	9
7. Pharmacokinetic drug interactions	9
8. Other pharmacokinetic studies	9
9. Discussions and conclusions	9
10. Chart	Ten
References	Ten

LIST OF TABLES

Table 1 Luciferase RNA-encapsulated LNP intravenously to Wistar Han rats at a dose of 1 mg RNA / kg Pharmacokinetics of ALC-0315 and ALC-0159 when administered orally	Four
---	------

LIST OF FIGURES

Figure 1 Luciferase RNA-encapsulated LNP venous in Wistar Han rats at a dose of 1 mg RNA / kg Plasma and liver concentrations of ALC-0315 and ALC-0159 when administered orally	5
Figure 2 In vivo in BALB / c mice intramuscularly administered with luciferase RNA-encapsulated LNP Luminous	6
Figure 3 Estimated in vivo metabolic pathway of ALC-0315 in various animal species	8
Figure 4 Estimated in vivo metabolic pathway of ALC-0159 in various animal species	9

PFIZER CONFIDENTIAL
Page 1

Page 2

Masking location: Adjusting

Figure D1.2 – Pfizer LNP Distribution (Page 2)

SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048)
2.6.4 Summary of pharmacokinetic study

Terms and abbreviations used in this section	
Term / Abbreviation	Not abbreviated expressions or definitions
ALC-0159	PEG lipid added to this drug
ALC-0315	Amino lipid added to this drug
[3 H]-CHE	Radiolabeled [cholesteryl-1,2- 3 H (N)] - cholesteryl hexadecyl Ether: radiolabeled [cholesteryl Lil-1, 2-3 H (N)] Hexadecyl ether
DSPC	1,2-distearoyl-sn-glycero-3-phosphocholine: 1,2-distearoyl-sn-glycero-3-phosphocholine
GLP	Good Laboratory Practice: Criteria for conducting non-clinical studies on drug safety
LNP	Lipid-nanoparticle: Lipid nanoparticle
modRNA	Nucleoside-modified mRNA: Modified nucleoside mRNA
mRNA	Messenger RNA: Messenger RNA
m / z	m / z (m over z): Obtained by dividing the mass of an ion by the unified atomic mass unit (= Dalton).
PEG	The dimensionless quantity obtained by dividing the obtained dimensionless quantity by the absolute value of the number of charges of the ion.
PK	Polyethylene glycol: Polyethylene glycol
RNA	Pharmacokinetics: Pharmacokinetics
S9	Ribonucleic acid: Ribonucleic acid
WHO	Supernatant fraction obtained from liver homogenate by centrifuging at 9000 g: liver homogenate
	Supernatant fraction centrifuged at 9000 g
	World Health Organization: World Health Organization

PFIZER CONFIDENTIAL
Page 2

Masking location: Adjusting

SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048)
2.6.4 Summary of pharmacokinetic study

1. Summary

BNT162b2 (BioNTech code number: BNT162, Pfizer code number: PF-07302048) is a severe acute call.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein (S protein) full length

It is a modified nucleoside mRNA (modRNA) that encodes against SARS-CoV-2 infection.

Development is underway as the essence of the mRNA vaccine. When formulating BNT162b2, there are two

Functional lipids ALC-0315 (aminolipid) and ALC-0159 (PEG lipid) and two structural lipids

By mixing with DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) and cholesterol

Figure D1.3 – Pfizer LNP Distribution (Page 3)

Lipid nanoparticles (LNP) that encapsulate BNT162b2 are formed (hereinafter, "BNT162b2-encapsulated LNP").

ALC-0315 and ALC-0159 contained in LNP to evaluate the nonclinical pharmacokinetics of BNT162b2 encapsulated LNP

In vivo and in vitro studies assessing absorption (PK), metabolism and excretion of ALC-0159 and BNT162b2

Biodistribution studies using luciferase or radiolabeled lipids as an alternative reporter for

Was carried out.

Based on the fact that the development of vaccines aimed at preventing infectious diseases does not require evaluation of systemic exposure.

(WHO, 2005; Non-clinical study guidelines for infectious disease preventive vaccines) [1](#), [2](#), BNT162b2 Encapsulated LNP muscle

No internal PK study was performed. In addition, two other types of lipids (cholesterol) contained in this drug

Rolls and DSPCs) are naturally occurring lipids that are thought to be metabolized and excreted in the same way as endogenous lipids.

available. In addition, BNT162b2 is degraded by ribonucleases in the cells that have taken it up, resulting in nucleic acid charges.

Apologize, the S protein from BNT162b2 is expected to undergo proteolysis. From the above,

It was considered unnecessary to evaluate the metabolism and excretion of these components again.

LNP (Luciferase) encapsulating RNA encoding luciferase as an alternative reporter for BNT162b2

Lase RNA is encapsulated in an LNP having the same lipid composition as the BNT162b2-encapsulated LNP:

In a PK study in which ZeRNA-encapsulated LNP *) was intravenously administered to Wistar Han rats, plasma, urine, feces and

Liver samples were collected over time and the concentrations of ALC-0315 and ALC-0159 in each sample were measured. The conclusion

As a result, ALC-0315 and ALC-0159 were shown to be rapidly distributed from the blood to the liver. Also,

About 1% and about 50% of the doses of ALC-0315 and ALC-0159 are excreted in feces as unchanged drug, respectively.

All of them were below the detection limit in urine.

In the biodistribution test, luciferase RNA-encapsulated LNP was intramuscularly administered to BALB / c mice. That

As a result, the expression of luciferase was observed at the administration site, and the expression level was lower than that in the liver.

Was also recognized. Expression at the administration site of luciferase was observed from 6 hours after administration, and 9 days after administration.

Disappeared. Expression in the liver was also observed 6 hours after administration and disappeared by 48 hours after administration. Also,

Intramuscular administration of radiolabeled LNP containing luciferase RNA to rats to quantify biodistribution

Upon evaluation, the radioactivity concentration was the highest at the administration site. Liver is highest except at the administration site

It was good (up to 18% of the dose).

Metabolism of ALC-0315 and ALC-0159 in CD-1 / ICR mice, Wistar Han or Sprague Dawley rats,

In vitro using cynomolgus monkey or human blood, liver microsomes, liver S9 fraction and hepatocytes

evaluated. In addition, plasma, urine, feces and liver samples collected in the above rat intravenous administration PK test were used.

We also examined in vivo metabolism. From these in vitro and in vivo studies, ALC-0315 and

ALC-0159 was added to ester and amide bonds in all animal species tested.

The solution showed that it was slowly metabolized.

PFIZER CONFIDENTIAL

Page 3

Page 4

Masking location: Adjusting

SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048)

2.6.4 Summary of pharmacokinetic study

From the above nonclinical pharmacokinetic evaluation, it was shown that LNP that reached the circulating blood is distributed in the liver.

In addition, metabolism and fecal excretion may be involved in the disappearance of ALC-0315 and ALC-0159, respectively.

It was suggested.

2. Analytical method

Report number: PF-07302048_06 [_072424](#)

Intravenous administration of rats without GLP PK test (M2.6.4.3), ALC-0315, which is a constituent lipid of LNP, and

ALC-0159 We have developed an LC / MS method with appropriate performance for quantifying the concentration. That is, 20 µL

Plasma, liver homogenate (homogenates are prepared using sections collected from three parts of the liver, and they are used.

Dilute with a blank matrix as appropriate), urine and fecal homogenate (as appropriate, bran)

Dilute with kumatrix) Divide each sample with acetonitrile containing an internal standard substance (PEG-2000)

After protein, it was centrifuged and the supernatant was subjected to LC-MS / MS measurement.

3. Absorption

Report number: PF-07302048_06 [_072424](#), Summary table: [2.6.5.3](#)

Male luciferase RNA-encapsulated LNP to study the pharmacokinetics of ALC-0315 and ALC-0159

A single intravenous dose of 1 mg RNA / kg was administered to Wistar Han rats over time (pre-dose, post-dose 0.1, 0.25,

Figure D1.4 – Pfizer LNP Distribution (Page 4)

Sparse plasma and liver 0.5, 1, 3, 6 and 24 hours and 2, 4, 8 and 14 days after dosing)

Sampling was performed (3 animals / time point). ALC-0315 and ALC-0159 in plasma and liver

The concentration was measured and the PK parameters were calculated (Table 1). ALC-0315 and ALC-0159 in the blood are thrown

It was promptly distributed to the liver by 24 hours after administration. In addition, the plasma concentration 24 hours after administration is the highest in plasma.

It was less than 1% of the concentration (Figure 1). The apparent terminal phase elimination half-life (t½) is in plasma and liver

At the same level, ALC-0315 took 6 to 8 days and ALC-0159 took 2 to 3 days. From the results of this test, the liver is in the blood

It was suggested that it is one of the major organizations that take up ALC-0315 and ALC-0159 from.

Results of examination of urinary and fecal concentrations of ALC-0315 and ALC-0159 conducted in this study

Is M2.6.4. Described in Section 6 .

Table 1 Intravenous injection of luciferase RNA- encapsulated LNP into Wistar Han rats at a dose of 1 mg RNA / kg

Pharmacokinetics of ALC-0315 and ALC-0159 when given						
Analytical material	Dosage of analyte (mg / kg)	Gender / N	t½ (h)	AUC inf (µg • h / mL)	AUC last (Mg • h / mL)	To the liver Distribution ratio (%) a
ALC-0315	15.3	Male / 3 b	139	1030	1020	60
ALC-0159	1.96	Male / 3 b	72.7	99.2	98.6	20

Calculated as [maximum liver distribution (µg)] / [dose (µg)].

b. 3 animals at each time point. Sparse sampling.

PFIZER CONFIDENTIAL


Page 4

SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048)

2.6.4 Summary of pharmacokinetic study

Masking location: Adjusting

Figure 1 Intravenous injection of luciferase RNA- encapsulated LNP into Wistar Han rats at a dose of 1 mg RNA / kg



4. Distribution

Report number: R- -0072 , 185350, Summary table: 2.6.5.5A, 2.6.5.5B

Female BALB / c mice (3 mice) were administered luciferase RNA-encapsulated LNP to emit luciferase luminescence.

The biodistribution of BNT162b2 was examined as an alternative marker. That is, luciferase RNA inclusion

LNP was intramuscularly administered to the left and right hind limbs of mice at a dose of 1 µg RNA (2 µg RNA in total). After that, Le

Intraperitoneal administration of luciferin, a luminescent substrate, 5 minutes before detection of ciferase luminescence, isoflurane hemp

Intoxication, in vivo luminescence 6 and 24 hours after administration using Xenogen IVIS Spectrum and 2,

By measuring on days 3, 6 and 9, the expression of luciferase protein in the same individual was estimated over time.

Evaluated the transfer. As a result, expression of luciferase at the administration site was observed from 6 hours after administration, and it was administered.

Figure D2.1 – Vaccine Metallic Contaminants (Page 1)

Investigation of metallic contaminations found
in vector- and mRNA-based
COVID-19-”vaccines”
- Preliminary results -

March 2022

Figure D2.2 – Vaccine Metallic Contaminants (Page 2)

1 Summary

Different vials of mRNA-based COVID-19-"vaccines" (Biontech and Moderna) are investigated by means of Scanning Electron Microscopy (SEM) and corresponding Energy Dispersive X-ray Spectroscopy (EDX) to study potential contaminations. Metallic particles comprising transition metals (e.g. cobalt (Co), iron (Fe), chromium (Cr), titanium (Ti)), rare earth metals such as cerium (Ce) and gadolinium (Gd), barium (Ba), caesium (Cs), aluminium (Al), silicon (Si), sulfur (S), potassium (K) and calcium (Ca) are found. The size of the particles varies from $1\mu\text{m}$ to $100\mu\text{m}$. In contrast, first investigations of the compounds of Johnson&Johnson (Janssen), Lubecavax, and Influspit Tetra yielded did not show signs of such contaminations and particles up to now. However, further confirmation and measurements are necessary and planned for the near future.

2 Experimental section

Different samples of COVID-19-"vaccines" are investigated by SEM/EDX. In a scanning electron microscope (SEM), the sample in question is scanned by means of a narrowly focused electron beam ($5\text{-}10\text{nm}$) of several thousand electron volts energy. In the studies presented here, energy of 15000 eV (15 keV) was used, and secondary electrons were used for imaging. In addition to imaging the surface of the sample at very high resolution, chemical analysis can be performed using energy dispersive X-ray spectroscopy (EDX). At the energy of 15 keV used here, a detection depth of some micrometers is achieved.

The samples were leftovers from vials which could not be used for injection anymore or vials where the cooling chain was interrupted. The samples were prepared for REM/EDX in two different ways. Firstly, a number of microscope slides were covered with a thin film of Gold (Au) for electrical conductivity required for the measurements. The vaccine samples have been drawn up with syringes exactly as it is done before injecting person to be vaccinated. Then, the vaccine samples were dripped from the syringe onto the Au covered slide. The vaccine dried for several days under ambient conditions protected from any contamination, before the samples were brought into the SEM. Secondly, other lots of COVID-19-"vaccines" were prepared in a different lab. Here, the vials were opened and the samples were directly casted onto microscope slides, were the samples dried for several days under ambient conditions protected from contamination. Then, the samples were sent to the SEM-lab. Since these microscope slides were not covered with Au,

Figure D2.3 – Vaccine Metallic Contaminants (Page 3)

the slides were covered with a thin iridium (Ir) film prior to the SEM/EDX measurements to ensure the required electrical conductivity. Note that the EDX detector used contains a carbon based window, hence the signals from carbon and oxygen in the EDX-spectra are not entirely reliable.

3 Results

The following reference sample, a sample of the protein based vaccine Lubecavax, and a number of lots of novel COVID-19-”vaccines” have been studied with SEM/EDX:

- an empty microscope slide as reference
- Lubecavax (Prof. Stöcker)
- AstraZeneca (Vaxzevria): lot 210101 and lot 1423474
- Biontech-Pfizer (Cormirnaty) lot FE7011, lot FE8045, and lot 1F1010A
- Moderna (Spikevax), lot 3004217

Figure D2.4 – Vaccine Metallic Contaminants (Page 4)

3.1 Empty microscope slide

Figure 1 shows a SEM image of several mm^2 area of an empty microscope slide taken directly from the original packaging. The slide was covered with a thin film of Ir to ensure electrical conductivity directly before measurement. The slide is homogenous with a few microscopic scratches. The EDX-map indicates also a homogenous distribution of the chemical elements identified in the EDX-spectrum, i.e. Na), Mg, Al, K, Ca, and the main component is Si (likely SiO_2).




Figure 1: Top left: SEM image of an empty microscope slide. Top right: EDX map. Bottom: EDX sum spectrum of the mapped area.

Figure D2.5 – Vaccine Metallic Contaminants (Page 5)

3.2 Lubecavax

This sample was prepared in another lab for SEM/EDX-experiments. In this case the sample holder was covered with a thin platinum (Pt) film prior to the SEM/EDX measurements to ensure the required electrical conductivity. Figure 2 displays a typical SEM image of the protein component of Lubecavax. The EDX-point spectra show a spot with more Na and chlorine (Cl) (likely NaCl) (spot1) and a spot with more organic components (spot4), Except low amounts of S and K no other contaminations are found.




Figure 2: Top: SEM image of the dried protein component of Lubecavax-vaccine. Center and bottom: EDX point spectra of dried vaccine (spots 1 and 4). Note that Pt does not belong to the sample probed by EDX due to the sample preparation described above.

Figure D2.6 – Vaccine Metallic Contaminants (Page 6)

3.3 AstraZeneca (Vaxzevria: lot 210101)

This sample was prepared via a syringe on a gold covered microscope slide as described in section 2. The EDX-spectrum shown in Fig.3 is typical for the dried Vaxzevria-”vaccine”, it consists of some Na und Cl (likely NaCl) and mainly of organic ingredients.




Figure 3: Top: SEM image of dried vaccine. Bottom: EDX point spectrum of dried vaccine (site 457), marked by a blue frame.

Appendix E: Full Vaxxanalysis Report (Forensic Imaging)

Figure D3.1 – Full Report: Vaccine Metallic Contaminants (Page 1)

Investigation of metallic contaminations found
in vector- and mRNA-based
COVID-19-”vaccines”
- Preliminary results -

March 2022

Figure D3.2 – Full Report: Vaccine Metallic Contaminants (Page 2)

1 Summary

Different vials of mRNA-based COVID-19-"vaccines" (Biontech and Moderna) are investigated by means of Scanning Electron Microscopy (SEM) and corresponding Energy Dispersive X-ray Spectroscopy (EDX) to study potential contaminations. Metallic particles comprising transition metals (e.g. cobalt (Co), iron (Fe), chromium (Cr), titanium (Ti)), rare earth metals such as cerium (Ce) and gadolinium (Gd), barium (Ba), caesium (Cs), aluminium (Al), silicon (Si), sulfur (S), potassium (K) and calcium (Ca) are found. The size of the particles varies from $1\mu\text{m}$ to $100\mu\text{m}$. In contrast, first investigations of the compounds of Johnson&Johnson (Janssen), Lubecavax, and Influspit Tetra yielded did not show signs of such contaminations and particles up to now. However, further confirmation and measurements are necessary and planned for the near future.

2 Experimental section

Different samples of COVID-19-"vaccines" are investigated by SEM/EDX. In a scanning electron microscope (SEM), the sample in question is scanned by means of a narrowly focused electron beam ($5\text{-}10\text{nm}$) of several thousand electron volts energy. In the studies presented here, energy of 15000 eV (15 keV) was used, and secondary electrons were used for imaging. In addition to imaging the surface of the sample at very high resolution, chemical analysis can be performed using energy dispersive X-ray spectroscopy (EDX). At the energy of 15 keV used here, a detection depth of some micrometers is achieved.

The samples were leftovers from vials which could not be used for injection anymore or vials where the cooling chain was interrupted. The samples were prepared for REM/EDX in two different ways. Firstly, a number of microscope slides were covered with a thin film of Gold (Au) for electrical conductivity required for the measurements. The vaccine samples have been drawn up with syringes exactly as it is done before injecting person to be vaccinated. Then, the vaccine samples were dripped from the syringe onto the Au covered slide. The vaccine dried for several days under ambient conditions protected from any contamination, before the samples were brought into the SEM. Secondly, other lots of COVID-19-"vaccines" were prepared in a different lab. Here, the vials were opened and the samples were directly casted onto microscope slides, were the samples dried for several days under ambient conditions protected from contamination. Then, the samples were sent to the SEM-lab. Since these microscope slides were not covered with Au,

Figure D3.3 – Full Report: Vaccine Metallic Contaminants (Page 3)

the slides were covered with a thin iridium (Ir) film prior to the SEM/EDX measurements to ensure the required electrical conductivity. Note that the EDX detector used contains a carbon based window, hence the signals from carbon and oxygen in the EDX-spectra are not entirely reliable.

3 Results

The following reference sample, a sample of the protein based vaccine Lubecavax, and a number of lots of novel COVID-19-”vaccines” have been studied with SEM/EDX:

- an empty microscope slide as reference
- Lubecavax (Prof. Stöcker)
- AstraZeneca (Vaxzevria): lot 210101 and lot 1423474
- Biontech-Pfizer (Cormirnaty) lot FE7011, lot FE8045, and lot 1F1010A
- Moderna (Spikevax), lot 3004217

Figure D3.4 – Full Report: Vaccine Metallic Contaminants (Page 4)

3.1 Empty microscope slide

Figure 1 shows a SEM image of several mm^2 area of an empty microscope slide taken directly from the original packaging. The slide was covered with a thin film of Ir to ensure electrical conductivity directly before measurement. The slide is homogenous with a few microscopic scratches. The EDX-map indicates also a homogenous distribution of the chemical elements identified in the EDX-spectrum, i.e. Na), Mg, Al, K, Ca, and the main component is Si (likely SiO_2).




Figure 1: Top left: SEM image of an empty microscope slide. Top right: EDX map. Bottom: EDX sum spectrum of the mapped area.

Figure D3.5 – Full Report: Vaccine Metallic Contaminants (Page 5)

3.2 Lubecavax

This sample was prepared in another lab for SEM/EDX-experiments. In this case the sample holder was covered with a thin platinum (Pt) film prior to the SEM/EDX measurements to ensure the required electrical conductivity. Figure 2 displays a typical SEM image of the protein component of Lubecavax. The EDX-point spectra show a spot with more Na and chlorine (Cl) (likely NaCl) (spot1) and a spot with more organic components (spot4), Except low amounts of S and K no other contaminations are found.




Figure 2: Top: SEM image of the dried protein component of Lubecavax-vaccine. Center and bottom: EDX point spectra of dried vaccine (spots 1 and 4). Note that Pt does not belong to the sample probed by EDX due to the sample preparation described above.

Figure D3.6 – Full Report: Vaccine Metallic Contaminants (Page 6)

3.3 AstraZeneca (Vaxzevria: lot 210101)

This sample was prepared via a syringe on a gold covered microscope slide as described in section 2. The EDX-spectrum shown in Fig.3 is typical for the dried Vaxzevria-”vaccine”, it consists of some Na und Cl (likely NaCl) and mainly of organic ingredients.




Figure 3: Top: SEM image of dried vaccine. Bottom: EDX point spectrum of dried vaccine (site 457), marked by a blue frame.

Figure D3.7 – Full Report: Vaccine Metallic Contaminants (Page 7)

Figure 4 shows a SEM image of a contamination found in this sample. An EDX point spectrum taken at site 616 (c.f. Fig 4) reveals the presence of silver (Ag) as well as traces of S, Co, Ce and Gd localized in this contamination. The other point scans taken yield in similar results. The surrounding material is the organic part of the "mRNA-vaccine" exposed to the electron radiation.




Figure 4: Top: SEM image of a contamination. Bottom: EDX point spectrum of site 616 (marked by a blue frame).

Figure D3.8 – Full Report: Vaccine Metallic Contaminants (Page 8)

3.4 AstraZeneca (Vaxzevria: lot 1423474)

This sample was prepared at another lab opening the vial and then preparing the sample as described in section 2. Figure 5 shows a SEM image of a contamination found in this sample. An EDX point spectrum taken at site 616 (c.f. Fig 5) reveals the presence of Al and S, but also Ca, Fe, and Ti present in this contamination. The other point scans taken yield in similar results.




Figure 5: Top: SEM image of a contamination. Bottom: EDX point spectrum of site 107 (marked by a blue frame). Note that Ir does not belong to the sample probed by EDX due to the sample preparation described in 2.

Figure D3.9 – Full Report: Vaccine Metallic Contaminants (Page 9)

3.5 Biontech-Pfizer (Cormirnaty: lot FE7011)

This sample was prepared via a syringe on a gold covered microscope slide as described in section 2. The EDX-spectrum shown in Fig.6 is typical for the dried Cormirnaty-"vaccine", it consists mainly of Na und Cl (likely NaCl), phosphorus (P), which may stem from some of the lipids, and organic ingredients.




Figure 6: Top: SEM image of dried vaccine including contamination in the center. Bottom: EDX point spectrum of dried vaccine (site 225), marked by a blue frame.

Figure D3.10 – Full Report: Vaccine Metallic Contaminants (Page 10)

Figure 7 displays a SEM image of a contamination consisting of Si only as can be seen from the corresponding EDX-spectrum.




Figure 7: Top: SEM image of dried vaccine and a Si-contamination in the center. Bottom: EDX point spectrum of the Si (site 224), marked by a blue frame.

Figure D3.11 – Full Report: Vaccine Metallic Contaminants (Page 11)

Figure 8 displays an Fe-containing particle found in this sample. The particles dimensions are $\approx 2.5\mu\text{m} \times 2.0\mu\text{m}$




Figure 8: Top: SEM image of a $2.5\mu\text{m}$ wide contamination. Bottom: EDX point spectrum of the Fe containing particle (site 237), marked by a blue frame.

Figure D3.12 – Full Report: Vaccine Metallic Contaminants (Page 12)

3.6 Biontech-Pfizer (Cormirnaty: lot FE8045)

This sample was prepared at another lab opening the vial and then preparing the sample as described in section 2. Figure 9 shows a SEM image of a contamination consisting mainly of Ca, traces of Si are also present.




Figure 9: Top: SEM image of a contamination of 40-50 μ m size. Bottom: EDX point spectrum of this contamination (site 70), marked by a blue frame. Note that Ir does not belong to the sample probed by EDX due to the sample preparation described in 2.

Figure D3.13 – Full Report: Vaccine Metallic Contaminants (Page 13)

Figure 10 shows a SEM image of a contamination comprising a number of chemical elements. Besides Mg, Al, Si, S, K, and Ca also the 3d transition metals Ti and Fe are detected. The other point spectra recorded at this contamination yield to similar results in terms of the elements detected, with partly changing stoichiometry.




Figure 10: Top: SEM image of a contamination of 25-30 μm size. Bottom: EDX point spectrum of this contamination (site 96), marked by a blue frame. Note that Ir does not belong to the sample probed by EDX due to the sample preparation described in 2.

Figure D3.14 – Full Report: Vaccine Metallic Contaminants (Page 14)

Figure 11 (top left) shows a SEM image of a particle in the form of a sphere. This sphere consists mainly of Al, some Ca and traces of Fe are also present as can be seen from the element specific spatial EDX mapping results.




Figure 11: Top left: SEM image of a sphere of $3\mu\text{m}$ diameter. Top right: Element specific EDX mapping of Al. Bottom: element specific EDX mappings of Ca and Fe.

Figure D3.15 – Full Report: Vaccine Metallic Contaminants (Page 15)

3.7 Biontech-Pfizer (Cormirnaty: lot 1F1010A)

This sample was prepared at another lab opening the vial and then preparing the sample as described in section 2. Figure 12 shows a SEM image of a contamination consisting mainly of S, Some Fe is also present. Furthermore, traces of Na, Al, Si, and Ca are detected. The other point scans taken yield in similar results, with partly changing stoichiometry.




Figure 12: Top: SEM image of a contamination of $40\mu\text{m} \times 10\mu\text{m}$ size. Bottom: EDX point spectrum of this contamination (site 371), marked by a blue frame. Note that Ir does not belong to the sample probed by EDX due to the sample preparation described in 2.

Figure D3.16 – Full Report: Vaccine Metallic Contaminants (Page 16)

Figure 13 shows a SEM image of a contamination comprising significant amounts of Ti, traces of Na, Al, Si, S, and Ca are also detected.




Figure 13: Top: SEM image of a particle of $5\mu\text{m}$ size. Bottom: EDX point spectrum of this particle (site 394), marked by a blue frame. Note that Ir does not belong to the sample probed by EDX due to the sample preparation described in 2.

Figure D3.17 – Full Report: Vaccine Metallic Contaminants (Page 17)

3.8 Moderna (Spikevax: lot 3004217)

This sample was prepared via a syringe on a gold covered microscope slide as described in section 2. The EDX-spectrum shown in Fig.14 is typical for the dried Spikevax-” vaccine”, it consists of Na und Cl (likely NaCl), traces of P, which may stem from some of the lipids, and manly, organic ingredients.




Figure 14: Top: SEM image of dried vaccine. Bottom: EDX point spectrum of dried vaccine (site 68), marked by a blue frame.

Figure D3.18 – Full Report: Vaccine Metallic Contaminants (Page 18)

This sample was prepared via a syringe on a gold covered microscope slide as described in section 2. Figure 15 shows a SEM image of a contamination comprising significant amounts of Si. Besides traces of Na, Mg, Al, P, S, Cl, and Ca also the metals Cs, Cr, Fe, and copper (Cu) are detected.




Figure 15: Top: SEM image of a particle of $50\mu\text{m}$ size. Bottom: EDX point spectrum of this particle (site 21), marked by a blue frame.

Figure D3.19 – Full Report: Vaccine Metallic Contaminants (Page 19)

This sample was prepared via a syringe on a gold covered microscope slide as described in section 2. Figure 16 (top left) shows a SEM image of a rod like contamination. This rod like structure consists mainly of Si, some Ca and Al are also present as can be seen from the element specific spatial EDX mapping results.




Figure 16: Top left: SEM image of a rod like structure of $20\mu\text{m}$ length. Top right: Element specific EDX mapping of Si. Bottom: element specific EDX mappings of Ca and Al.

Figure D3.20 – Full Report: Vaccine Metallic Contaminants (Page 20)

This sample was prepared from a vial of the same lot but at another lab opening the vial and then preparing the sample as described in section 2. Figure 17 shows a SEM image of a contamination comprising significant amounts of Si, Ti, and Fe. Traces of Na, Mg, Al, K, and Ca are also detected.




Figure 17: Top: SEM image of a particle of 15-20 μm size. Bottom: EDX point spectrum of this particle (site 380), marked by a blue frame. Note that Ir does not belong to the sample probed by EDX due to the sample preparation described in 2.

Figure D3.21 – Full Report: Vaccine Metallic Contaminants (Page 21)

This sample was prepared from a vial of the same lot but at another lab opening the vial and then preparing the sample as described in section 2. Figure 18 shows a SEM image of a contamination comprising significant amounts of Al, Si, S, and Ba. Traces of Na, Mg, S, Cl, K, Ca, Ce, Cr, and Fe are also detected.




Figure 18: Top: SEM image of a contamination of 20-30 μ m size. Bottom: EDX point spectrum of this particle (site 179), marked by a blue frame. Note that Ir does not belong to the sample probed by EDX due to the sample preparation described in 2.

